Images (3)

Pfizer Vaccination

  • Genome Released

    Genome Released
    The SARS-CoV-2 genome was released.
  • Studies

    Studies
    Preclinical studies for the vaccine start.
  • The First Pfizer Vaccine Trial Started

    The First Pfizer Vaccine Trial Started
    The very first trial for the vaccine started to make sure it's safe.
  • Phase 2 Vaccine Trial

    Phase 2 Vaccine Trial
    The second phase for the pfizer vaccine started.
  • Phase 3 Clinical Trial

    Phase 3 Clinical Trial
    The third trial for the vaccine started.
  • Emergency Use

    Emergency Use
    Some countries approved the vaccine for emergency use.
  • FDA Releases Pfizer Data

    FDA Releases Pfizer Data
    The FDA released the data for the pfizer vaccine clinical trials on their website.
  • First Pfizer Vaccine Given

    First Pfizer Vaccine Given
    The first pfizer vaccine outside of the trial was given to a 90 year old women in Northern Ireland.
  • FDA Approves First Covid Vaccine

    FDA Approves First Covid Vaccine
    The FDA approved the very first Covid-19 vaccine. This vaccine was the Pfizer-BioNTech COVID-19 Vaccine.
  • Pfizer Asks FDA to Approve Booster Shot

    Pfizer Asks FDA to Approve Booster Shot
    Pfizer has done research and now is asking for the FDA to approve a booster shot.
  • Vaccine Loses Effectiveness

    Vaccine Loses Effectiveness
    The Pfizer vaccine reduces the risk of being hospitalized with COVID-19 by 91% in the first four months, but reduces to 77% after 120 days.
  • Booster Shot

    Booster Shot
    The FDA has authorized a booster shot for the vaccine.
  • FDA Approved Pfizer Booster Shot

    FDA Approved Pfizer Booster Shot
    The FDA approved a 3rd booster shot for the pfizer vaccine for certain candidates.
  • Oral Vaccine

    Oral Vaccine
    Pfizer has started researching how to take an oral vaccine instead of a shot.
  • Children Getting the Vaccine

    Children Getting the Vaccine
    Pfizer has submitted their research to the FDA for kids 5-11 to get the vaccine.